NCT06930755 (ClinicalTrials.gov Identifier: NCT06930755) is a Phase 1 clinical trial evaluating the combination of an investigational non-trapping PARP1-specific PARP inhibitor, NMS-03305293, administered orally, with topotecan, administered intravenously, in adult patients with relapsed ovarian cancer (specifically high-grade serous epithelial ovarian, fallopian tube, or peritoneal cancer). The trial is part of a multicenter research effort.

The study is designed to assess the safety and tolerability of this investigational combination therapy, as well as to evaluate anti-tumor activity and pharmacokinetics, with all treatment approaches being studied for research purposes in accordance with the approved study protocol.

“OSF HealthCare remains deeply committed to advancing early-phase oncology research tailored to gynecologic malignancies, including the complexities of relapsed ovarian cancer, through strategic collaborations with innovative biotechnology partners to bring promising clinical trials directly to our patients,” said Dr. Michelle Rowland, Translational Researcher and Gynecologic Oncologist, OSF HealthCare Cancer Institute. “Participating in these important studies allows us to provide eligible patients facing relapsed ovarian cancer with potential access to novel investigational therapies that address significant unmet needs in managing this recurrent and difficult-to-treat disease.”

All clinical research conducted at OSF HealthCare undergoes rigorous review and ongoing oversight to help ensure patient safety and ethical conduct.

Patients interested in learning more about clinical research at OSF HealthCare are encouraged to speak with their care team, call (844) 673-4467 or email sfmc.clinicaltrials@osfhealthcare.org.